 | • レポートコード：QFJ1-5034 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、ワルデンストレームマクログロブリン血症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（CB-839、コパンリシブ塩酸塩、DI-B4、エントスプレチニブ、エベロリムス、FV-162、その他）、用途別市場規模（クリニック、病院、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・ワルデンストレームマクログロブリン血症治療薬の市場動向 ・企業の競争状況、市場シェア ・ワルデンストレームマクログロブリン血症治療薬の種類別市場規模と予測2016-2027（CB-839、コパンリシブ塩酸塩、DI-B4、エントスプレチニブ、エベロリムス、FV-162、その他） ・ワルデンストレームマクログロブリン血症治療薬の用途別市場規模と予測2016-2027（クリニック、病院、その他） ・ワルデンストレームマクログロブリン血症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・ワルデンストレームマクログロブリン血症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・ワルデンストレームマクログロブリン血症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ワルデンストレームマクログロブリン血症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・ワルデンストレームマクログロブリン血症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（BeiGene(Beijing) Co.,Ltd、Calithera Biosciences, Inc.、Celgene Corporation、Genentech, Inc.、Genmab A/S、Gilead Sciences, Inc.、Hutchison MediPharma Limited、Idera Pharmaceuticals, Inc.、IGF Oncology, LLC.、Incyte Corporation、Karyopharm Therapeutics, Inc.、Merck KGaA、Millennium Pharmaceuticals, Inc.） ・結論 |
Market Analysis and Insights: Global Waldenstrom Macroglobulinemia Therapeutics Market
The global Waldenstrom Macroglobulinemia Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Waldenstrom Macroglobulinemia Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Waldenstrom Macroglobulinemia Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Waldenstrom Macroglobulinemia Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Waldenstrom Macroglobulinemia Therapeutics market.
Global Waldenstrom Macroglobulinemia Therapeutics Scope and Market Size
Waldenstrom Macroglobulinemia Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Waldenstrom Macroglobulinemia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
CB-839
Copanlisib Hydrochloride
DI-B4
Entospletinib
Everolimus
FV-162
Others
Segment by Application
Clinic
Hospital
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
BeiGene(Beijing) Co.,Ltd
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 CB-839
1.2.3 Copanlisib Hydrochloride
1.2.4 DI-B4
1.2.5 Entospletinib
1.2.6 Everolimus
1.2.7 FV-162
1.2.8 Others
1.3 Market by Application
1.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Perspective (2016-2027)
2.2 Waldenstrom Macroglobulinemia Therapeutics Growth Trends by Regions
2.2.1 Waldenstrom Macroglobulinemia Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Waldenstrom Macroglobulinemia Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Waldenstrom Macroglobulinemia Therapeutics Industry Dynamic
2.3.1 Waldenstrom Macroglobulinemia Therapeutics Market Trends
2.3.2 Waldenstrom Macroglobulinemia Therapeutics Market Drivers
2.3.3 Waldenstrom Macroglobulinemia Therapeutics Market Challenges
2.3.4 Waldenstrom Macroglobulinemia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Waldenstrom Macroglobulinemia Therapeutics Players by Revenue
3.1.1 Global Top Waldenstrom Macroglobulinemia Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Waldenstrom Macroglobulinemia Therapeutics Revenue
3.4 Global Waldenstrom Macroglobulinemia Therapeutics Market Concentration Ratio
3.4.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Waldenstrom Macroglobulinemia Therapeutics Revenue in 2020
3.5 Waldenstrom Macroglobulinemia Therapeutics Key Players Head office and Area Served
3.6 Key Players Waldenstrom Macroglobulinemia Therapeutics Product Solution and Service
3.7 Date of Enter into Waldenstrom Macroglobulinemia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Waldenstrom Macroglobulinemia Therapeutics Breakdown Data by Type
4.1 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Type (2022-2027)
5 Waldenstrom Macroglobulinemia Therapeutics Breakdown Data by Application
5.1 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
6.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
6.2.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2027)
6.3 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
6.3.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2027)
6.4 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
6.4.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
7.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
7.2.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2027)
7.3 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
7.3.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2027)
7.4 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
7.4.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
8.2.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
8.3.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Region
8.4.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
9.2 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
9.2.1 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
9.3.1 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
9.4.1 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
10.2.1 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
10.3.1 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
10.4.1 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 BeiGene(Beijing) Co.,Ltd
11.1.1 BeiGene(Beijing) Co.,Ltd Company Details
11.1.2 BeiGene(Beijing) Co.,Ltd Business Overview
11.1.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Introduction
11.1.4 BeiGene(Beijing) Co.,Ltd Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.1.5 BeiGene(Beijing) Co.,Ltd Recent Development
11.2 Calithera Biosciences, Inc.
11.2.1 Calithera Biosciences, Inc. Company Details
11.2.2 Calithera Biosciences, Inc. Business Overview
11.2.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.2.4 Calithera Biosciences, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.2.5 Calithera Biosciences, Inc. Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Details
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Introduction
11.3.4 Celgene Corporation Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.3.5 Celgene Corporation Recent Development
11.4 Genentech, Inc.
11.4.1 Genentech, Inc. Company Details
11.4.2 Genentech, Inc. Business Overview
11.4.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.4.4 Genentech, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.4.5 Genentech, Inc. Recent Development
11.5 Genmab A/S
11.5.1 Genmab A/S Company Details
11.5.2 Genmab A/S Business Overview
11.5.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Introduction
11.5.4 Genmab A/S Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.5.5 Genmab A/S Recent Development
11.6 Gilead Sciences, Inc.
11.6.1 Gilead Sciences, Inc. Company Details
11.6.2 Gilead Sciences, Inc. Business Overview
11.6.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.6.4 Gilead Sciences, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.6.5 Gilead Sciences, Inc. Recent Development
11.7 Hutchison MediPharma Limited
11.7.1 Hutchison MediPharma Limited Company Details
11.7.2 Hutchison MediPharma Limited Business Overview
11.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Introduction
11.7.4 Hutchison MediPharma Limited Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.7.5 Hutchison MediPharma Limited Recent Development
11.8 Idera Pharmaceuticals, Inc.
11.8.1 Idera Pharmaceuticals, Inc. Company Details
11.8.2 Idera Pharmaceuticals, Inc. Business Overview
11.8.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.8.4 Idera Pharmaceuticals, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.8.5 Idera Pharmaceuticals, Inc. Recent Development
11.9 IGF Oncology, LLC.
11.9.1 IGF Oncology, LLC. Company Details
11.9.2 IGF Oncology, LLC. Business Overview
11.9.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.9.4 IGF Oncology, LLC. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.9.5 IGF Oncology, LLC. Recent Development
11.10 Incyte Corporation
11.10.1 Incyte Corporation Company Details
11.10.2 Incyte Corporation Business Overview
11.10.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Introduction
11.10.4 Incyte Corporation Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.10.5 Incyte Corporation Recent Development
11.11 Karyopharm Therapeutics, Inc.
11.11.1 Karyopharm Therapeutics, Inc. Company Details
11.11.2 Karyopharm Therapeutics, Inc. Business Overview
11.11.3 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.11.4 Karyopharm Therapeutics, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.11.5 Karyopharm Therapeutics, Inc. Recent Development
11.12 Merck KGaA
11.12.1 Merck KGaA Company Details
11.12.2 Merck KGaA Business Overview
11.12.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Introduction
11.12.4 Merck KGaA Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.12.5 Merck KGaA Recent Development
11.13 Millennium Pharmaceuticals, Inc.
11.13.1 Millennium Pharmaceuticals, Inc. Company Details
11.13.2 Millennium Pharmaceuticals, Inc. Business Overview
11.13.3 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Introduction
11.13.4 Millennium Pharmaceuticals, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
11.13.5 Millennium Pharmaceuticals, Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of CB-839
Table 3. Key Players of Copanlisib Hydrochloride
Table 4. Key Players of DI-B4
Table 5. Key Players of Entospletinib
Table 6. Key Players of Everolimus
Table 7. Key Players of FV-162
Table 8. Key Players of Others
Table 9. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Regions (2016-2021)
Table 13. Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Regions (2022-2027)
Table 15. Waldenstrom Macroglobulinemia Therapeutics Market Trends
Table 16. Waldenstrom Macroglobulinemia Therapeutics Market Drivers
Table 17. Waldenstrom Macroglobulinemia Therapeutics Market Challenges
Table 18. Waldenstrom Macroglobulinemia Therapeutics Market Restraints
Table 19. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Players (2016-2021)
Table 21. Global Top Waldenstrom Macroglobulinemia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Waldenstrom Macroglobulinemia Therapeutics as of 2020)
Table 22. Ranking of Global Top Waldenstrom Macroglobulinemia Therapeutics Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Waldenstrom Macroglobulinemia Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Waldenstrom Macroglobulinemia Therapeutics Product Solution and Service
Table 26. Date of Enter into Waldenstrom Macroglobulinemia Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2016-2021)
Table 30. Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2016-2021)
Table 34. Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 66. BeiGene(Beijing) Co.,Ltd Company Details
Table 67. BeiGene(Beijing) Co.,Ltd Business Overview
Table 68. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product
Table 69. BeiGene(Beijing) Co.,Ltd Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 70. BeiGene(Beijing) Co.,Ltd Recent Development
Table 71. Calithera Biosciences, Inc. Company Details
Table 72. Calithera Biosciences, Inc. Business Overview
Table 73. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product
Table 74. Calithera Biosciences, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Calithera Biosciences, Inc. Recent Development
Table 76. Celgene Corporation Company Details
Table 77. Celgene Corporation Business Overview
Table 78. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product
Table 79. Celgene Corporation Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Celgene Corporation Recent Development
Table 81. Genentech, Inc. Company Details
Table 82. Genentech, Inc. Business Overview
Table 83. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product
Table 84. Genentech, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Genentech, Inc. Recent Development
Table 86. Genmab A/S Company Details
Table 87. Genmab A/S Business Overview
Table 88. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product
Table 89. Genmab A/S Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 90. Genmab A/S Recent Development
Table 91. Gilead Sciences, Inc. Company Details
Table 92. Gilead Sciences, Inc. Business Overview
Table 93. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product
Table 94. Gilead Sciences, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Gilead Sciences, Inc. Recent Development
Table 96. Hutchison MediPharma Limited Company Details
Table 97. Hutchison MediPharma Limited Business Overview
Table 98. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product
Table 99. Hutchison MediPharma Limited Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Hutchison MediPharma Limited Recent Development
Table 101. Idera Pharmaceuticals, Inc. Company Details
Table 102. Idera Pharmaceuticals, Inc. Business Overview
Table 103. Idera Pharmaceuticals, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Idera Pharmaceuticals, Inc. Recent Development
Table 105. IGF Oncology, LLC. Company Details
Table 106. IGF Oncology, LLC. Business Overview
Table 107. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product
Table 108. IGF Oncology, LLC. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 109. IGF Oncology, LLC. Recent Development
Table 110. Incyte Corporation Company Details
Table 111. Incyte Corporation Business Overview
Table 112. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product
Table 113. Incyte Corporation Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 114. Incyte Corporation Recent Development
Table 115. Karyopharm Therapeutics, Inc. Company Details
Table 116. Karyopharm Therapeutics, Inc. Business Overview
Table 117. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product
Table 118. Karyopharm Therapeutics, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 119. Karyopharm Therapeutics, Inc. Recent Development
Table 120. Merck KGaA Company Details
Table 121. Merck KGaA Business Overview
Table 122. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product
Table 123. Merck KGaA Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 124. Merck KGaA Recent Development
Table 125. Millennium Pharmaceuticals, Inc. Company Details
Table 126. Millennium Pharmaceuticals, Inc. Business Overview
Table 127. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product
Table 128. Millennium Pharmaceuticals, Inc. Revenue in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021) & (US$ Million)
Table 129. Millennium Pharmaceuticals, Inc. Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. CB-839 Features
Figure 3. Copanlisib Hydrochloride Features
Figure 4. DI-B4 Features
Figure 5. Entospletinib Features
Figure 6. Everolimus Features
Figure 7. FV-162 Features
Figure 8. Others Features
Figure 9. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Application: 2020 VS 2027
Figure 10. Clinic Case Studies
Figure 11. Hospital Case Studies
Figure 12. Others Case Studies
Figure 13. Waldenstrom Macroglobulinemia Therapeutics Report Years Considered
Figure 14. Global Waldenstrom Macroglobulinemia Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Waldenstrom Macroglobulinemia Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Regions: 2020 VS 2027
Figure 17. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Regions (2022-2027)
Figure 18. Global Waldenstrom Macroglobulinemia Therapeutics Market Share by Players in 2020
Figure 19. Global Top Waldenstrom Macroglobulinemia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Waldenstrom Macroglobulinemia Therapeutics as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Waldenstrom Macroglobulinemia Therapeutics Revenue in 2020
Figure 21. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2016-2021)
Figure 22. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2022-2027)
Figure 23. North America Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Waldenstrom Macroglobulinemia Therapeutics Market Share by Type (2016-2027)
Figure 25. North America Waldenstrom Macroglobulinemia Therapeutics Market Share by Application (2016-2027)
Figure 26. North America Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2016-2027)
Figure 27. United States Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Waldenstrom Macroglobulinemia Therapeutics Market Share by Type (2016-2027)
Figure 31. Europe Waldenstrom Macroglobulinemia Therapeutics Market Share by Application (2016-2027)
Figure 32. Europe Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2016-2027)
Figure 33. Germany Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Share by Region (2016-2027)
Figure 43. China Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Share by Type (2016-2027)
Figure 51. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Share by Application (2016-2027)
Figure 52. Latin America Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2016-2027)
Figure 53. Mexico Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Share by Country (2016-2027)
Figure 59. Turkey Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Waldenstrom Macroglobulinemia Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. BeiGene(Beijing) Co.,Ltd Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 63. Calithera Biosciences, Inc. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 64. Celgene Corporation Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 65. Genentech, Inc. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 66. Genmab A/S Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 67. Gilead Sciences, Inc. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 68. Hutchison MediPharma Limited Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 69. Idera Pharmaceuticals, Inc. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 70. IGF Oncology, LLC. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 71. Incyte Corporation Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 72. Karyopharm Therapeutics, Inc. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 73. Merck KGaA Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 74. Millennium Pharmaceuticals, Inc. Revenue Growth Rate in Waldenstrom Macroglobulinemia Therapeutics Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界のアテローム性動脈硬化症治療薬市場規模・現状・予測（2021年-2027年） Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as th…- 世界の抗菌治療薬市場規模・現状・予測（2021年-2027年） An antimicrobial is an agent that kills microorganisms or stops their growth. The increasing prevalence of deadly diseases such as HIV and HPV has created the need for high-quality diagnostics which will enable early diagnosis of the infection. Technological advancements in the healthcare industry h…
- 世界の糖鎖生物学（診断＆治療）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Glycobiology (Diagnostics and Therapeutics) Market The global Glycobiology (Diagnostics and Therapeutics) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in …
- 世界の未分化甲状腺がん治療薬市場規模・現状・予測（2021年-2027年） Anaplastic thyroid cancer is one of four types ofthyroid cancer. It's very rare: The American ThyroidAssociation notes that this type represents less than 2 percent of all cases of thyroid cancer. Market Analysis and Insights: Global Anaplastic Thyroid Cancer Therapeutics Market The global Anaplasti…
- 世界の小児がん治療市場規模・現状・予測（2021年-2027年） Children are affected by different forms of cancer than adults, there also exists a major difference between children and adults regarding treatment and development of new oncology therapies. The prominent variation is the concept of survival. With adult cancer patients, it is acceptable to look to …